



## **ASX ANNOUNCEMENT**

### **Swine Influenza Vaccines**

*Imugene advances swine influenza vaccine project*

**28 April 2009, Sydney, Australia.** In response to the significant recent press coverage and shareholder enquiries, Imugene releases the following information to the market regarding our Swine Influenza vaccine projects.

The Imugene laboratory has developed a suite of poultry vaccines for potential use in chickens against H5, H7 and H9 strains of avian influenza using the Fowl Adenovirus Vector. The Porcine Adenovirus Vector is equally suitable for the production of Swine Influenza vaccines for use in pigs.

Imugene's Swine Influenza vaccine development program commenced in early 2008 and has identified both H1N1 and H3N2 vaccines as potential vaccines for development. Swine Influenza is a respiratory viral disease of pigs and outbreaks occur throughout many parts of the world. Vaccination against Swine Influenza is routine in many countries. Imugene is to produce two vaccines, one each for the H1 and H3 strains. The vaccines will take approximately a further 4-8 weeks to complete the laboratory construction phase.

The Swine Influenza vaccines may then enter the product development program if commercial parameters are satisfied and the market deemed sufficiently large. To date, Imugene has rated other pig diseases as higher commercial priorities and there are already other Swine Influenza vaccines available. Accordingly, the Imugene Swine Influenza vaccines are predominantly to expand our available range of vaccines against existing and developing pig diseases of commercial significance.

#### **About Imugene**

Imugene specialises in commercialising animal health products for production animals including pigs and poultry.

Imugene owns the worldwide rights to the *Fowl Adenoviral Vector Delivery System* for poultry and the *Porcine Adenoviral Vector Delivery System* for pigs. Since establishing a laboratory at La-Trobe University, Victoria, additional vaccine technology has been developed for the pig & poultry industries.

A Strategic Alliance with Merial Limited agreed in December 2008, provides the strength of Merial's vast experience and infrastructure to the development of Imugene's innovative range of vaccine candidates. In return for exclusivity over the Imugene technology, Imugene will receive annual payments, milestone fees and royalties.

ABN 99 009 179 551

Registered Office

Level 20, Allendale Square, 77 St Georges Terrace, Perth WA 6000  
Tel +61 8 94402660 Fax +61 8 9 4402699

[www.imugene.com](http://www.imugene.com)

Imugene's poultry and pig vaccine portfolio is targeting a worldwide US\$3 billion annual market with several lead vaccine products under development and a strong product pipeline. Consumer demands for disease free and residue free food will bolster Imugene's prospects.

For more information please visit the Imugene Website [www.imugene.com](http://www.imugene.com) or contact:

**Dr Warwick Lamb**  
**Managing Director**  
**+61 2 9870 7330**

**Mr Graham Dowland**  
**Executive Chairman**  
**+61 8 9440 2660**